You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for New Drug Application (NDA): 206677

✉ Email this page to a colleague

« Back to Dashboard

NDA 206677 describes PENTOBARBITAL SODIUM, which is a drug marketed by Lannett, Vitarine, Whiteworth Town Plsn, Bpi Labs, Elkins Sinn, Hikma, and Sagent Pharms Inc, and is included in nine NDAs. It is available from two suppliers. Additional details are available on the PENTOBARBITAL SODIUM profile page.

The generic ingredient in PENTOBARBITAL SODIUM is pentobarbital sodium. There are two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the pentobarbital sodium profile page.

Summary for 206677

Tradename:	PENTOBARBITAL SODIUM
Applicant:	Bpi Labs
Ingredient:	pentobarbital sodium
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	50MG/ML
Approval Date:	Nov 27, 2017	TE:	AP	RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.